Some may be worried about buying now. They are concerned that the Roth CC will be disappointing. There is nothing to worry about. Bad news is not going to be released. But there might be some titillating good news released. That will give the pps a little pop. But even if there is not, so what?
Looming over this stock is the simple fact that there will be an interim analysis released. When? Could be in a week or two or a couple of months. Nobody knows when. However that bit of certainty provides a solid floor of support. Remember, even the ever negative guru when it comes to small biotechs, Adam Feuerstein, said the announcement would pop the pps a buck or two.
At some point you will start accumulating just because there is too much positive potential in the future. If you start now is that too early, maybe? But in the very near future the current pps will look awfully cheap. JMHO.
Cheers and GLTA.
Agree, whether you believe in the drug or not, it will not be at this pps when results are released later on this year/early next year. IMHO if do not feel they would stop the trial at interim even if ICT-107 was not showing any benefit. Why would they? The drug appears very safe and what would it hurt to continue the trial until the very end even if there is no seperation between treatment and control at interim. ONTY's stimuvax was obviously not showing any efficacy at their interim analysis however the safety committee agreed that the trial should go on. Why, because the drug appeared safe. Personally I want to own my shares now as I see a pop in the pps after the they agree the drug is safe and the trial should continue. I do not see them stopping the trial because of poor futility. I think some less risk tolerant investors are waiting on the sidelines until this safety analysis and then will be purchasing their shares thus hopefully increasing the pps.
Exactly. Receiving approval to continue the trial at the Interim is a slam dunk. Not only did ONTY receive approval to continue the trial according to current protocols, so did Celsion. ICT-107 has very few side-effects and given the outstanding results of Phase I it will not be deemed futile.
The DMC is definitely going to grant approval for the trial to continue with existing protocols. Bingo, a one to two dollar pop. Now is the time to accumulate. Cheers.